Novel Broad Spectrum Antivirals
Drug Development Phase: Pre-clinical
Kineta’s Innate Immune Antiviral program offers a proprietary discovery platform and compounds with a novel mechanism of action that activate the innate immune transcription factor IRF-3, a critical first responder that is essential for inhibiting viral replication and clearing infection.
Unlike direct acting antivirals, these host directed compounds have demonstrated efficacy across a broad spectrum of respiratory, hepatitis B and emerging viruses and offer the potential for a pan-viral therapy that circumvents drug resistance. These developmental products will be used as first-line oral or IV treatment for multiple viral infections. No equivalent drug currently exists in the market.
Kineta’s innate immune antivirals address critical unmet needs in therapeutic areas that represent significant commercial potential and an opportunity to optimize lifecycle management. This program has a broad global patent estate.